-
CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study
•
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from the Center for Drug Evaluation (CDE) to conduct a clinical study for SYS6002, an antibody-drug conjugate (ADC) developed in-house by its subsidiary CSPC Jushi Biopharmaceutical Co., Ltd. The intended indication for SYS6002 is advanced solid…
-
CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co., Ltd, has entered into a licensing agreement with US-based Elevation Oncology Inc. (NASDAQ: ELEV). The deal grants Elevation exclusive development and commercialization rights to CSPC Jushi’s Claudin 18.2 (CLDN18.2) antibody drug conjugate (ADC) candidate SYSA1801…
